PRISM Early-Stage Parkinson’s Disease Study
CONDITION: Early-stage Parkinson’s Disease
COMPENSATION: May be available
The PRISM Parkinson’s Research Study is evaluating an investigational drug to determine if it might slow down the progression of Parkinson’s disease (PD). Patients who enroll in this study will receive the study drug weekly over a period of 36 weeks. Participants will have about 10 scheduled in-person visits at the study center and 5 scheduled telephone visits. Those who enroll can expect to be in the study for a total of 44 weeks.
Who Can Participate
Participants between 30 and 80 years of age who are diagnosed with early-stage Parkinson’s Disease and are not on any current treatments for the disease.